Mesothelioma: your questions and future treatment options Susie Harden 1/4/11.

Slides:

Advertisements

Similar presentations

Advances and Emerging Therapy for Lung Cancer

Advertisements

Staging. Treatment by Stage For early stage lung cancers, surgery or radiation alone For larger tumors (>4 cm) and N+, chemotherapy should be added.

What are clinical trials? Phases of Clinical Trials Clinical trials of new medicines are done in phases: Phase I Phase II Phase III.

Phase Difference = Phase Difference = 0.05.

PCR Application: Can Breast Cancer be Cured?. Normal, Healthy Cells Cells can change or differentiate to become specialised according to the tissue that.

Postoperative Radiation for Oral Cavity Squamous Cell Carcinoma: The EP.

Upper gastrointestinal cancers

Understanding and Treating Triple-Negative Breast Cancer Elshami M. Elamin, MD Medical Oncologist Central Care Cancer Center Wichita,

Anbazhagan R. Classification of Small Cell Lung Cancer and Pulmonary Carcinoid by Gene Expression Profiles. Cancer research. 1999; 59:5119 –5122.

MH: 42 – 44 N: Cancer: Cell Division Gone Wrong.

ERCC 1 isoform expression and DNA repair in NSCLC

Lung cancer perspectives. Targeted therapy : one for all or a few for one ? Miklos Pless, Winterthur

Afsha Rais.  In chromatins, DNA is wrapped around proteins of which most are histones.  Histones assist in DNA packaging and have a regulatory role.

Systemic Treatment of Metastatic Colorectal Cancer: Living with a Moving Landscape Neal J. Meropol, MD Fox Chase Cancer Center May 16, 2005.

Treatment for metastatic bladdercancer (chemotherapy&radiotherapy) Dr.Mina Tajvidi oncologist.

Treatment Regimens of HER2+ Adjuvant Patients (Actuals) Source: Genentech ASCO 2005 (data release) Nov 2006 (Approval)

Cancer Potential Treatments. What is it? Cancer is a group of diseases characterized by too much mitosis. A tumour (a group of cells that do not perform.

MBCG Project Primary Results MEDICALSURVEYS-17 RESEARCH GROUP IN COLLABORATION WITH THE EASO.

Discovery of 7-(4-(3-Ethynylphenylamino)-7- methoxyquinazolin-6-yloxy)-N-hydroxyheptanamide (CUDC-101) as a Potent Multi-Acting HDAC, EGFR, and HER2 Inhibitor.

CH Mutations in Genes Objectives: 1.Describe the following types of mutations: a.Base substitution b.Base insertion or deletion 2. Explain what can.

Mesothelioma Nasty form of cancer Attributed to inhalation of asbestos fibers People who worked with or near asbestos typically at most risk.

ESMO 2011 Lung Cancer Vantage 014 Study Authors: Dr. Sunil Verma Date posted: September 28 th, 2011.

Esophageal Cancer: A Critical Evaluation of Systemic Second-Line Therapy Christiane Maria Rosina Thallinger, Markus Raderer, and Michael Hejna J Clin Oncol.

종양혈액내과 R4 고원진 / pf. 김시영 Rectal cancer : state of the art in 2012 Curr Opin Oncol 2012, 24:441–447.

Treatment options in mesothelioma

Presented By Lorenz Trumper at 2016 ASCO Annual Meeting

Final Results from a Phase 2 Study of Pracinostat in Combination with Azacitidine in Elderly Patients with Acute Myeloid Leukemia (AML)1 CC-486 (Oral.

© The Author(s) Published by Science and Education Publishing.

N Engl J Med; Volume 373(17): ; October 22, 2015

Presented By Luca Malorni at 2017 ASCO Annual Meeting

How have evolutions in strategies for the treatment of relapsed/refractory multiple myeloma translated into improved outcomes for patients? Pieter Sonneveld,

Caris Molecular Intelligence®

Chemotherapy of malignant tumors

HOW AIDS CAUSED&TREATMENT

Chlamydocin Chlamydocin is a cyclic tetrapeptide. Chlamydocin is a very potent inhibitor of cell proliferation. Chlamydocin was shown to be a very potent.

Figure 2 Underreporting by physicians of specific treatment-associated symptoms by physicians in the TORCH trial Figure 2 | Underreporting by physicians.

Program Goals. Program Goals What is Atopic Dermatitis?

Figure 1 Key time points in the discovery and development of imatinib for the treatment of chronic myeloid leukaemia (CML) and gastrointestinal stromal.

Therapeutic Strategies in the Management of Mild-to-Moderate Atopic Dermatitis.

THE CONTINUUM OF CARE IN mCRC: OPTIMIZING USE OF EGFR ANTIBODIES

Tailoring Hemophilia Prophylaxis Therapy

Three major reactions in all cells The Fate of Ammonium Three major reactions in all cells Carbamoyl-phosphate synthetase I two ATP required - one.

EGFR Inhibitors in Advanced NSCLC: Who, When, and Why?

Volume 56, Issue 3, Pages (March 2012)

Therapeutic targeting of the tumor microenvironment

Immunotherapy for cSCC

Mutational Testing to Select Novel Targeted Therapies in AML

© University of Cambridge

A Randomized Phase II Study Adding Axitinib to Pemetrexed-Cisplatin in Patients with Malignant Pleural Mesothelioma: A Single-Center Trial Combining Clinical.

Antitumor activity of BAY in patient-derived tumor models.

Best Practices in Lymph Node Mapping and Localization: Melanoma

Chapter 3 Treatment guidelines for NSCLC that does not have targetable driver mutations.

Tetsuya Mitsudomi, MD, Hirohito Tada, MD Journal of Thoracic Oncology

Putting Evidence Into Practice: Highlights From Toronto

First-Line Afatinib versus Chemotherapy in Patients with Non–Small Cell Lung Cancer and Common Epidermal Growth Factor Receptor Gene Mutations and Brain.

Defining Patient-Centered Care: Spotlight on Advanced Non-Small Cell Lung Cancer.

Nat. Rev. Urol. doi: /nrurol

Managing Patients with Relapsed CLL who Discontinue BCR Signaling Inhibitors.

Background: Gene Expression

Optimizing Treatment in HR-Positive Breast Cancer: A Case-Based Discussion.

Practical Guidance on the Management of Pan-Negative NSCLC

Challenges in LA SCCHN.

Epigenetics modification

Chapter 18: Chromosome A Cell Nucleus 54,830 bp 552 aa SMAD4

This program will include a discussion of off-label treatment or use of investigational agents not approved by the FDA for use in the US, and data that.

Checkpoint Inhibitors in First-Line Advanced NSCLC

Third-Generation EGFR TKIs

Folic Acid, Methotrexate, Pemetrexed

Tyrosine kinase inhibitors

Updates in Best Practices in Non-Small Cell Lung Cancer

Presentation transcript:

Mesothelioma: your questions and future treatment options Susie Harden 1/4/11

Future possibilities in Cambridge n First line studies n Second line studies n Phase 1 studies n Biobank: potential for individually tailored treatments in the future?

First line studies coming soon n MESO 2: phase II study of adding vorinostat to pemetrexed /cisplatin [this agent is a histone deacetylase inhibitor and acts to ‘unblock’ certain genes in tumour cells n ADAM: Phase II study of pegylated arginine deaminase/placebo [when chemotherapy not indicated in ASS (arginosuccinate synthetase) negative patients. (this agent depletes tumours of an essential amino acid – arginine)]

Secondline studies No standard treatment but re-challenge with pemetrexed if good first time response accepted No imminent trials in Cambridge

Phase 1 studies in Cambridge n S SHINOGI [a dual EGFR and HER2 small molecule inhibitor] n Radiotherapy (your feedback please!) Tomotherapy dose-wash diagram

Over to you! Any questions? Any suggestions?